Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
After recovery, please store the organoid in its maintenance medium under the correct incubation condition and medium changing process.
Protocol Diagram of cerebral organoid differentiation.
Left: A day 32 cerebral organoid exhibits rosette-like neural stem cell structures, which diminish as development progresses.
Right: A day 109 cerebral organoid displays uniform morphology with no evidence of central necrosis.
Presence of TH and MAP2 positive neurons in day 92 cerebral organoid.
TH: used as cell marker of dopaminergic neurons.
MAP2: mature neuron cell marker.
Left: Presence of GFAP positive cells at day 109 cultured cerebral organoid.
Right: Presence of OLIG2 positive cells at day 119 cultured cerebral organoid.
GFAP: marker for astrocyte.
OLIG2: marker for oligodendrocyte.
Using cerebral organoids for modelling Parkinson's Disease. Cerebral organoids are treated with Human Alpha-Synuclein Pre-formed Fibrils Protein. Dopaminergic neurons and MAP2 positive neurons are damaged with both 0.1 μM and 1 μM Alpha-Synuclein Pre-formed Fibrils.
AAVs selection using cerebral organoids: Different capsid of AAVs were incubated with cerebral organoids. As the results, different affinities of each AAV to the cerebral organoid were observed.
Human Tau-441 K18 (P301L) Pre-formed Fibrils Protein, Tag Free (TAU-H5113) induce tau phosphorylation and astrocyte activation in brain organoids (DIV100+, CIPO-BWL002K).
In brain organoids (CIPO-BWL002K), Human Tau-441 K18 Pre-formed Fibrils Protein, Tag Free (TAU-H5116) dose-dependently upregulate IL-1β, IL-6 and IL-8, increase the tau phosphorylation at Thr217 and suppress SOD2, indicating that PFF treatment induces tau phosphorylation, neuroinflammation and disrupts antioxidant balance.
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
This web search service is supported by Google Inc.
A-Z
